Jim Cramer has raised concerns over the constitutionality of recent drug price controls, urging pharmaceutical companies to seek an injunction.
What Happened: CNBC’s Mad Money host, Cramer, in a post on X on Monday, argued that, unlike tariffs, drug price controls fall under the Commerce Clause of the Constitution and suggested they may not hold up under legal scrutiny.
This follows President Donald Trump’s May 12, 2025, announcement to align U.S. drug prices with lower international …
Full story available on Benzinga.com
Jim Cramer has raised concerns over the constitutionality of recent drug price controls, urging pharmaceutical companies to seek an injunction.
What Happened: CNBC’s Mad Money host, Cramer, in a post on X on Monday, argued that, unlike tariffs, drug price controls fall under the Commerce Clause of the Constitution and suggested they may not hold up under legal scrutiny.
This follows President Donald Trump’s May 12, 2025, announcement to align U.S. drug prices with lower international …
Full story available on Benzinga.com
Jim Cramer has raised concerns over the constitutionality of recent drug price controls, urging pharmaceutical companies to seek an injunction.
What Happened: CNBC’s Mad Money host, Cramer, in a post on X on Monday, argued that, unlike tariffs, drug price controls fall under the Commerce Clause of the Constitution and suggested they may not hold up under legal scrutiny.
Price controls are not like tariffs. They are covered by the Commerce Clause of the Constitution. These drug controls most likely will not stand. The drug companies should move for an injunction today, or they are really ill-advised
— Jim Cramer (@jimcramer) May 12, 2025
This follows President Donald Trump’s May 12, 2025, announcement to align U.S. drug prices with lower international …Full story available on Benzinga.com Read Morebenzinga neuro, Big Pharma, Donald Trump, Drug Pricing, Drugmakers, Equities, News, Trump Drug Prices, Jim Cramer, Economics, Markets, General, News, Equities, Economics, Markets, General, Benzinga News
